{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T20:25:56Z","timestamp":1715977556115},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/cad.0000000000000020","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T15:43:13Z","timestamp":1381160593000},"page":"1-7","source":"Crossref","is-referenced-by-count":10,"title":["Zoledronic acid in the treatment of metastatic breast cancer"],"prefix":"10.1097","volume":"25","author":[{"given":"Ana","family":"Lluch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Alejandro","family":"P\u00e9rez-Fidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210227","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies.","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"R2-1-20210227","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1464-410X.1985.tb07040.x","article-title":"Generalised increase in bone resorption in carcinoma of the prostate.","volume":"57","author":"Urwin","year":"1985","journal-title":"Br J Urol"},{"key":"R3-1-20210227","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/ctrv.1999.0133","article-title":"Use of bisphosphonates for the treatment of bone metastasis in experimental animal models.","volume":"25","author":"Yoneda","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"R5-1-20210227","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer: implications for management.","volume":"36","author":"Plunkett","year":"2000","journal-title":"Eur J Cancer"},{"key":"R7-1-20210227","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CBC.2000.n.003","article-title":"Treatment of metastatic bone disease in breast cancer: bisphosphonates.","volume":"1","author":"Diel","year":"2000","journal-title":"Clin Breast Cancer"},{"key":"R9-1-20210227","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality.","volume":"104","author":"Coleman","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"R11-1-20210227","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JOP.2011.000212","article-title":"American Society of Clinical Oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer.","volume":"7","author":"Van Poznak","year":"2011","journal-title":"J Oncol Pract"},{"key":"R12-1-20210227","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.327.7413.469","article-title":"Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.","volume":"327","author":"Ross","year":"2003","journal-title":"Br Med J"},{"key":"R13-1-20210227","first-page":"CD003474","article-title":"Bisphosphonates for breast cancer.","volume":"3","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-1-20210227","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.clinthera.2009.05.009","article-title":"Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.","volume":"31","author":"Machado","year":"2009","journal-title":"Clin Ther"},{"key":"R15-1-20210227","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer.","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-1-20210227","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdm119","article-title":"Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.","volume":"18","author":"Body","year":"2007","journal-title":"Ann Oncol"},{"key":"R17-1-20210227","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00520-004-0659-5","article-title":"Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients.","volume":"12","author":"Romanus","year":"2004","journal-title":"Support Care Cancer"},{"key":"R26-1-20210227","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1634\/theoncologist.2007-0245","article-title":"Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.","volume":"15","author":"Aapro","year":"2010","journal-title":"Oncologist"},{"key":"R29-1-20210227","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s005200100249","article-title":"A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.","volume":"9","author":"DesHarnais Castel","year":"2001","journal-title":"Support Care Cancer"},{"key":"R31-1-20210227","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"key":"R35-1-20210227","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.23775","article-title":"Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.","volume":"113","author":"Hatoum","year":"2008","journal-title":"Cancer"},{"key":"R36-1-20210227","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clbc.2011.03.015","article-title":"Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.","volume":"11","author":"Hatoum","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"R41-1-20210227","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdl408","article-title":"Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.","volume":"18","author":"Aguiar Bujanda","year":"2007","journal-title":"Ann Oncol"},{"key":"R42-1-20210227","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000000020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:01:07Z","timestamp":1620946867000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201401000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000000020","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}